Editorial: Adnexal masses: When to observe, when to intervene, and when to refer

Obstetrics and Gynecology

Volumn 115, Issue 4, 2010, Pages 680-681

  Falcone, Tommaso ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CA 125 ANTIGEN;

ADNEXA DISEASE; CANCER MORTALITY; CANCER RISK; EDITORIAL; HIGH RISK PATIENT; MALIGNANT TRANSFORMATION; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; RISK ASSESSMENT; AGE; ECHOGRAPHY; FEMALE; HUMAN; MIDDLE AGED; NOTE; OVARY TUMOR; PATIENT REFERRAL; POSTMENOPAUSE; PREDICTION AND FORECASTING; PREMENOPAUSE; RISK FACTOR; SENSITIVITY AND SPECIFICITY;

AGE FACTORS; CA-125 ANTIGEN; FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; REFERRAL AND CONSULTATION; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 77949884960     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/AOG.0b013e3181d686ed     Document Type: Editorial

References (11)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Fader AN, Rose PG. Role of surgery in ovarian carcinoma. J Clin Onc 2007;25:2873-2883
3. Bell J, Brady MF, Young RC, Lage J, Walker JL, Look KY, et al. Randomized phase III trial of three versus six cycles of adjuvant carboplatin and paclitaxel in early stage epithelial ovarian carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006;102:432-439
4. McDonald JM, Doran S, DeSimone CP, Ueland FR, DePriest PD, Ware RA, et al. Predicting risk of malignancy in adnexal masses. Obstet Gynecol 2010;115:687-694
5. Valentin L, Hagen B, Tingulstad S, Eik-Nes S. Comparison of "pattern recognition" and logistic regression models for discrimination between benign and malignant pelvic masses. A prospective cross-validation. Ultrasound Obstet Gynecol 2001; 18:357-365
6. Management of adnexal masses. ACOG Practice Bulletin No. 83. American College of Obstetricians and Gynecologists. Obstet Gynecol 2007;110:201-214
7. Grimes DA, Jones LB, Lopez LM, Schulz KF. Oral contraceptives for functional ovarian cysts. The Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD006134. DOI: 10.1002/14651858.CD006134.pub3.
8. Roman LD, Muderspach LI, Steijn SM, Laifer-Narim S, Gro-shen S, Morrow CP. Pelvic examination, tumor marker, level, gray-scale and Doppler sonography in the prediction of pelvic cancer. Obstet Gynecol 1997;89:493-500.
9. Modesitt SC, Pavlik EJ, Ueland FR, DePriest PD, Kryscio RJ, van Nagell JR Jr. Risk of malignancy in unilocular ovarian cystic tumors less than 10 centimeters in diameter. Obstet Gynecol 2003;102:594-599
10. Bakkum-Gamez JN, Richardson D, Seamon L, Aletti G, Pow-less C, Keeney G, et al. Influence of intraoperative capsule rupture on outcomes in stage 1 epithelial ovarian cancer. Obstet Gynecol 2009;113:11-17
11. The role of the generalist obstetrician-gynecologist in the early detection of ovarian cancer. ACOG Committee Opinion No. 280. American College of Obstetricians and Gynecologists. Obstet Gynecol 2002;100:1413-1416